All News
Filter News
Found 806,106 articles
-
Provell Pharmaceuticals and Mark Cuban Cost Plus Drug Company Bring Leading Hypothyroid Drug, Euthyrox®, to U.S. Patients at Low-Cost Prices through Direct-to-Consumer Model
3/12/2024
Provell Pharmaceuticals, a healthcare company that distributes world-class, branded drugs at generic prices by eliminating middlemen markups, announced a partnership with Mark Cuban Cost Plus Drug Company, PBC to offer patients direct access to a leading hypothyroid drug, Euthyrox®, at low-cost prices on the Cost Plus Drugs online platform.
-
Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics
3/12/2024
Hyphens Pharma International Limited is pleased to announce that its subsidiary, Hyphens Pharma Pte. Ltd., has entered into an exclusive license, supply and commercialisation agreement with MC2 Therapeutics for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
-
Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics - March 12, 2024
3/12/2024
Beckman Coulter Diagnostics today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.
-
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
3/12/2024
Fractyl Health, Inc. announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
-
New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications
3/12/2024
DarioHealth Corp. announced two new clinical studies presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes 2024, held March 6 – 9 in Florence, Italy.
-
Theromics Inc. Receives National Science Foundation Grant for Innovative Ablation Therapy Technology
3/12/2024
Theromics Inc., a leading developer of products for the interventional oncology and interventional radiology markets, has announced the receipt of a $1M STTR Phase II grant from the National Science Foundation.
-
Dassault Systèmes and CDR-Life Collaborate to Accelerate Scientific Innovation for Cancer Therapies
3/12/2024
Dassault Systèmes announced it collaborated with CDR-Life, a Swiss biotherapeutics company, to accelerate CDR-Life’s development of next-generation highly tumor-selective immunotherapies using CDR-Life’s proprietary M-gager® platform.
-
Lamassu Awarded NIH Grant For Breakthrough Cancer Treatment
3/12/2024
Lamassu Bio Inc. has been awarded a grant from the National Institutes of Health and National Cancer Institute for the development of their groundbreaking treatment for p53 wild-type sarcomas.
-
Coya Therapeutics to Participate in BTIG Fireside Discussion
3/12/2024
Coya’s Scientific Board Chairman Dr. Stanley Appel and Chief Medical Officer Dr. Fred Grossman to participate in discussion hosted by BTIG Analyst Tom Shrader.
-
Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024
3/12/2024
Roche introduces navify Analytics, its suite of cloud-based solutions that provide actionable insights to optimise operational and financial outcomes in laboratories and point of care settings.
-
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
3/12/2024
Rigel Pharmaceuticals, Inc. announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer.
-
Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
3/12/2024
Tryp Therapeutics, Inc. is pleased to announce that the Company's securityholders overwhelmingly approved the previously announced arrangement involving the Company and Exopharm Limited CAN 163 765 991 at the Company's annual general and special meeting of securityholders held on March 8, 2024.
-
New International Study Reports Extension of the Donor Lung Transplantation Window
3/12/2024
Paragonix Technologies, Inc. announces the landmark publication of the first clinical manuscript assessing the use of FDA-cleared advanced organ preservation technology to significantly extend ischemic times, a term referring to the sensitive window of time between organ recovery and transplantation.
-
OncoOne Announces Formation of Clinical Advisory Board to Support Development of ON104 for Chronic Inflammatory Diseases
3/12/2024
OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.
-
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
3/12/2024
IGC Pharma, Inc. announced that it has appointed Terry Lierman as an independent director to its board of directors.
-
Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients
3/12/2024
Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients
-
Scorpius Holdings, Inc. Announces Closing of Public Offering - March 12, 2024
3/12/2024
Scorpius Holdings, Inc., an integrated contract development and manufacturing organization, announced the closing of its previously announced public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for gross proceeds of $1,500,000, before deducting underwriting discounts and offering expenses.
-
Truveris Announces C-Suite Appointments & Leadership Promotions
3/12/2024
Truveris elevates Garrett Fienberg to Chief Operating Officer, Gregg DiPietro to Chief Commercial Officer, and Louise Shea to Chief Pharmacy Officer.
-
DOMINION DIAGNOSTICS Earns 2024 Great Place To Work Certification™
3/12/2024
Dominion Diagnostics, a leading national medical laboratory specializing in urine drug monitoring solutions is proud to announce that it has been Certified™ by Great Place To Work® in 2024.
-
Nanox Announces AI Software Increases Identification of Patients with Vertebral Compression Fractures, an early sign of Osteoporosis, Up to Six-Fold
3/12/2024
NANO-X IMAGING LTD and its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd., announced that early findings from the ADOPT study, which uses a Nanox.AI artificial intelligence solution, HealthVCF, to review routine CT scans, have identified up to six times more patients with vertebral compression fracture than the national average at NHS hospitals in the UK, which include University of Oxford and other healthcare centers.